DLPIC
VRTX icon

Davide Leone & Partners Investment Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Davide Leone & Partners Investment Company’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-124,358
Closed -$27.2M – 20
2019
Q4 		$27.2M Buy
124,358
+47,800
+62% +$9.67M 3.49% 14
2019
Q3 		$13M Buy
+76,558
New +$13.5M 2.33% 10

Other funds holding VRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Davide Leone & Partners Investment Company's VRTX Position: Q1 2020 in Review

Davide Leone & Partners Investment Company sold out of Vertex Pharmaceuticals (VRTX) in Q1 2020, closing a stake of 124,358 shares — an estimated $27.2M sold.

Davide Leone & Partners Investment Company first reported a position in VRTX in Q3 2019 and held it in 2 quarters. The position peaked at $27.2M in Q4 2019. 856 funds tracked by Wall St. Rank hold VRTX as of Q1 2020.

  • Davide Leone & Partners Investment Company reported no remaining Vertex Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Davide Leone & Partners Investment Company sold 124,358 Vertex Pharmaceuticals shares in Q1 2020, an estimated $27.2M.
  • Davide Leone & Partners Investment Company first reported a position in Vertex Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • Davide Leone & Partners Investment Company's Vertex Pharmaceuticals position peaked at $27.2M in Q4 2019.
  • 856 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2020.

Based on Davide Leone & Partners Investment Company's 13F filing for Q1 2020, filed 15 May 2020.